In this study, we evaluated the antitumor efficacy of aAVC-WT1 in an aggressively growing mouse leukemia model and a first-in-human trial for elderly patients with RR-AML, who are known to have poor prognosis compared with younger counterparts.33 Here, WT1 is linked to leukemia.